Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2016 1
2017 2
2018 2
2019 2
2020 1
2021 3
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, Grünig E, Jansa P, Klinger JR, Langleben D, McLaughlin VV, Meyer GMB, Ota-Arakaki J, Peacock AJ, Pulido T, Rosenkranz S, Vizza CD, Vonk-Noordegraaf A, White RJ, Chang M, Kleinjung F, Meier C, Paraschin K, Ghofrani HA, Simonneau G; REPLACE investigators. Hoeper MM, et al. Lancet Respir Med. 2021 Jun;9(6):573-584. doi: 10.1016/S2213-2600(20)30532-4. Epub 2021 Mar 24. Lancet Respir Med. 2021. PMID: 33773120 Clinical Trial.
Riociguat might be an alternative option for patients with PAH who do not respond sufficiently to treatment with PDE5i, but comparisons of the potential benefits of riociguat and PDE5i in these patients are needed. ...METHODS: Riociguat rEplacing PDE5i …
Riociguat might be an alternative option for patients with PAH who do not respond sufficiently to treatment with PDE5i, but compariso …
Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study.
Simonneau G, Ghofrani HA, Corris PA, Rosenkranz S, Grünig E, White J, McLaughlin VV, Langleben D, Meier C, Busse D, Kleinjung F, Benza RL. Simonneau G, et al. Pulm Circ. 2020 Dec 9;10(4):2045894020973124. doi: 10.1177/2045894020973124. eCollection 2020 Oct-Dec. Pulm Circ. 2020. PMID: 33354316 Free PMC article.
The goal of treatment in patients with pulmonary arterial hypertension is to achieve a low risk status, indicating a favorable long-term outcome. The REPLACE study investigated the efficacy of switching to riociguat in patients with pulmonary arterial hypertension a …
The goal of treatment in patients with pulmonary arterial hypertension is to achieve a low risk status, indicating a favorable long-term out …
A focus on riociguat in the treatment of pulmonary arterial hypertension.
Toxvig AK, Wehland M, Grimm D, Infanger M, Krüger M. Toxvig AK, et al. Basic Clin Pharmacol Toxicol. 2019 Sep;125(3):202-214. doi: 10.1111/bcpt.13272. Epub 2019 Jul 4. Basic Clin Pharmacol Toxicol. 2019. PMID: 31206240 Free article. Review.
This MiniReview focuses on PAH treatment with riociguat and on its advantages and disadvantages compared with other drugs targeting the NO pathway. ...This finding was further examined in the REPLACE study (NCT02891850). Moreover, riociguat has shown promisin …
This MiniReview focuses on PAH treatment with riociguat and on its advantages and disadvantages compared with other drugs targeting t …
Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study.
Benza RL, Simonneau G, Ghofrani HA, Corris PA, Langleben D, Rosenkranz S, James White R, Cheng CC, Figueiredo Campos FTA, Kim HK, Souza R, Chang M, Rahner C, Meier C, Hoeper MM. Benza RL, et al. J Heart Lung Transplant. 2024 Jun 7:S1053-2498(24)01693-0. doi: 10.1016/j.healun.2024.06.002. Online ahead of print. J Heart Lung Transplant. 2024. PMID: 38852934
In REPLACE (NCT02891850), improvements in risk status were observed in patients with pulmonary arterial hypertension (PAH) at intermediate risk switching to riociguat vs continuing phosphodiesterase-5 inhibitors (PDE5i). ...Our findings show that patients in REPL …
In REPLACE (NCT02891850), improvements in risk status were observed in patients with pulmonary arterial hypertension (PAH) at interme …
Modern view on the place of riociguat in the treatment of pulmonary hypertension.
Valieva ZS, Taran IN, Martynyuk TV, Chazova IY. Valieva ZS, et al. Ter Arkh. 2018 Apr 19;90(4):55-59. doi: 10.26442/terarkh201890455-59. Ter Arkh. 2018. PMID: 30701875 Review.
Until recently, the only therapeutic strategy to influence the molecular pathway of nitric oxide (NO) - soluble guanylate cyclase (sGC) - cyclic guanosine monophosphate (cGMP) was the use of phosphodiesterase type 5 inhibitors (PDE-5 inhibitors), such as sildenafil. In September …
Until recently, the only therapeutic strategy to influence the molecular pathway of nitric oxide (NO) - soluble guanylate cyclase (sGC) - cy …
Emerging Role of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease-Insights from the 2022 ESC Guidelines.
Banaszkiewicz M, Kurzyna P, Kubikowska N, Mucha M, Rudnik A, Gąsecka A, Pietrasik A, Grabowski M, Jaguszewski MJ, Kasprzyk P, Kędzierski P, Ciećwierz D, Żuk G, Szwed P, Piłka M, Florczyk M, Kurzyna M, Darocha S. Banaszkiewicz M, et al. J Clin Med. 2023 Aug 16;12(16):5336. doi: 10.3390/jcm12165336. J Clin Med. 2023. PMID: 37629379 Free PMC article. Review.
Additionally, the benefits of pharmacological pre-treatment before BPA and the technical aspects of the procedure itself are outlined. It is emphasized that BPA does not replace PEA but serves as a complementary treatment option for eligible patients. We summarized efficac …
Additionally, the benefits of pharmacological pre-treatment before BPA and the technical aspects of the procedure itself are outlined. It is …
Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis.
Liu YY, Qu YY, Wang S, Luo CJ, Qiu HL, Li HT, Yuan P, Wang L, Li JL, Jiang R, Zhang R. Liu YY, et al. Front Pharmacol. 2023 Jan 26;14:1052546. doi: 10.3389/fphar.2023.1052546. eCollection 2023. Front Pharmacol. 2023. PMID: 36778016 Free PMC article.
Whether riociguat is more effective and safer than PDE-5is is ambiguous. We aimed to evaluate the efficacy and safety of switching from PDE-5is to riociguat among these patients. ...In addition, we did not observe the most common side effects during the replaceme …
Whether riociguat is more effective and safer than PDE-5is is ambiguous. We aimed to evaluate the efficacy and safety of switching fr …
[Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat].
Martynyuk TV, Shmalts AA, Gorbachevsky SV, Chazova IE. Martynyuk TV, et al. Ter Arkh. 2021 Sep 15;93(9):1117-1124. doi: 10.26442/00403660.2021.09.201014. Ter Arkh. 2021. PMID: 36286873 Russian.
After reviewing the mechanisms of action and the evidence base for specific therapy with phosphodiesterase 5 inhibitors (PDE-5) and soluble guanylate cyclase stimulators, a reseach review on switching from PDE-5 to riociguat is conducted. A potential advantage of riocig …
After reviewing the mechanisms of action and the evidence base for specific therapy with phosphodiesterase 5 inhibitors (PDE-5) and soluble …
16 results